2017•Leukemia & lymphoma/Leukemia and lymphomaRequires access
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study
Driss Chaoui, Sylvain Choquet, Laurence Sanhès, Beatrice Mahé, Maya Hacini, Olivier Fitoussi, Yazid Arkam, Hubert Orfeuvre, Marie‐Sarah Dilhuydy, Marly Barry, Éric Jourdan, Brigitte Dreyfus, Adrian Tempescul, Stéphane Leprêtre, A. Bardet, Pierre Leconte, Marc Maynadié, Alain Jacques Delmer
Open publisher page 5 citations
Abstract
This prospective non-interventional study assessed the management of relapsed/refractory CLL after one or two treatments with rituximab, and retreatment with a rituximab-based regimen. An interim analysis was performed at the end of the induction period in 192 evaluable patients. Median age was 72 years [35-89], first relapse (55%), and second relapse (45%). Rituximab administered during first (68%), second (92%), or both treatment lines (20%). R-bendamustine administered in 56% of patients, R-purine analogs (21%), and R-alkylating agents (19%). The overall response rate (ORR) was 74.6%, in favor of R-purine analogs (90%), R-bendamustine (75%), and R-alkylating agents (69%). Lower ORR in Del 17p patients (43%) and third time rituximab (31%). Most frequent adverse events were hematological (23% patients) including neutropenia (11%) and infections (12%); grade 3/4 AEs (23% patients), mainly hematological (18%); death during induction treatment (7%). This first large study focusing on relapsed/refractory CLL patients retreated with rituximab-based regimens is still ongoing.